ARN-3261 preferentially targets SIK2 and SIK3 (IC50 of 11 and 19 nM, respectively) and has been shown to sensitize ovarian cancer cell lines and xenografts to carboplatin (181) and is currently in Phase 1a/1b clinical trials in patients with ovarian, peritoneal and other solid tumors (278). This evidence concerns the gene SIK2 and ovarian carcinoma.